FCM
Farallon Capital Management Portfolio holdings
AUM
$21.3B
This Quarter Return
-10.02%
1 Year Return
+23.12%
3 Year Return
+87.19%
5 Year Return
+183.94%
10 Year Return
+836.54%
AUM
$10.9B
AUM Growth
+$10.9B
(-16%)
Cap. Flow
-$295M
Cap. Flow
% of AUM
-2.7%
Top 10 Holdings %
Top 10 Hldgs %
45.56%
Holding
134
New
16
Increased
36
Reduced
22
Closed
31
Top Buys
| 1 |
Centene
CNC
|
$431M |
| 2 |
AGN
Allergan plc
AGN
|
$232M |
| 3 |
IQVIA
IQV
|
$203M |
| 4 |
General Dynamics
GD
|
$146M |
| 5 |
Fidelity National Information Services
FIS
|
$138M |
Top Sells
| 1 |
WCG
Wellcare Health Plans, Inc.
WCG
|
$793M |
| 2 |
MDCO
Medicines Co
MDCO
|
$282M |
| 3 |
ZAYO
Zayo Group Holdings, Inc.
ZAYO
|
$236M |
| 4 |
S&P Global
SPGI
|
$175M |
| 5 |
AXE
Anixter International Inc
AXE
|
$84.5M |
Sector Composition
| 1 | Healthcare | 55.19% |
| 2 | Communication Services | 13.23% |
| 3 | Technology | 11.68% |
| 4 | Industrials | 5.78% |
| 5 | Financials | 4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Palo Alto Networks
PANW
$127B
| $162M | 1.39% | 986,721 -121,695 | -11% | -$20M |
|
27
Ascendis Pharma
ASND
$11.8B
| $155M | 1.33% | 1,376,349 +97,349 | +8% | +$11M |
|
28
TransUnion
TRU
$17.2B
| $134M | 1.15% | 2,023,887 +496,116 | +32% | +$32.8M |
|
|
BMY.RT
29
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $134M | 1.15% | 35,200,000 +4,825,050 | +16% | +$18.3M |
|
30
Qiagen
QGEN
$10.1B
| $123M | 1.06% | 2,960,986 +806,986 | +37% | +$33.6M |
|
|
FTSV
31
DELISTED
Forty Seven, Inc. Common Stock
FTSV
| $105M | 0.91% | +1,105,000 | New | +$105M |
|
32
Enanta Pharmaceuticals
ENTA
$180M
| $90M | 0.77% | 1,750,000 | – | – |
|
|
RARX
33
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $69.1M | 0.59% | 1,440,000 +251,900 | +21% | +$12.1M |
|
34
Fate Therapeutics
FATE
$120M
| $66.6M | 0.57% | 3,000,000 +750,000 | +33% | +$16.7M |
|
|
WMGI
35
DELISTED
Wright Medical Group Inc
WMGI
| $65.2M | 0.56% | 2,275,000 +1,585,000 | +230% | +$45.4M |
|
36
Grifois
GRFS
$6.78B
| $62.7M | 0.54% | 3,113,222 | – | – |
|
37
Zymeworks
ZYME
$1.12B
| $62.1M | 0.53% | 1,750,000 +50,000 | +3% | +$1.77M |
|
|
ZGNX
38
DELISTED
Zogenix, Inc.
ZGNX
| $55.6M | 0.48% | 2,250,000 +500,000 | +29% | +$12.4M |
|
39
FibroGen
FGEN
$47.8M
| $55.6M | 0.48% | 1,599,667 +249,667 | +18% | +$8.68M |
|
|
BRMK
40
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
| $53.9M | 0.46% | 7,170,213 -4,400 | -0.1% | -$33.1K |
|
41
Apellis Pharmaceuticals
APLS
$3.48B
| $53.6M | 0.46% | 2,000,000 +1,500,000 | +300% | +$40.2M |
|
|
PLYA
42
DELISTED
Playa Hotels & Resorts
PLYA
| $53.6M | 0.46% | 30,606,930 | – | – |
|
|
MRTX
43
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $46.1M | 0.4% | 600,000 +425,000 | +243% | +$32.7M |
|
44
Equifax
EFX
$30.3B
| $45.2M | 0.39% | 378,275 -273,914 | -42% | -$32.7M |
|
45
Agios Pharmaceuticals
AGIO
$2.19B
| $44.4M | 0.38% | 1,250,000 | – | – |
|
|
DCPH
46
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $41.2M | 0.35% | 1,000,000 +50,000 | +5% | +$2.06M |
|
|
KRTX
47
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $40.8M | 0.35% | 567,047 -32,953 | -5% | -$2.37M |
|
48
United Therapeutics
UTHR
$13.8B
| $34.6M | 0.3% | +365,000 | New | +$34.6M |
|
49
Sarepta Therapeutics
SRPT
$1.78B
| $34.2M | 0.29% | +350,000 | New | +$34.2M |
|
50
Veracyte
VCYT
$2.39B
| $33.4M | 0.29% | 1,375,000 +375,000 | +38% | +$9.12M |
|